MajorMacrolide antibiotic×Serotonin antagonist and reuptake inhibitor (SARI) antidepressant
Updated · Methodology
Mechanism
In the liver, the enzyme CYP3A4 mainly converts trazodone to its active metabolite (trazodone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and clarithromycin is a strong inhibitor of this enzyme (clarithromycin SmPC, AEMPS). Strong CYP3A4 inhibitors can raise trazodone plasma levels substantially: ritonavir 200 mg twice daily more than doubled them, and healthy volunteers developed nausea, syncope and hypotension (trazodone SmPC, AEMPS). Both drugs prolong the QT interval: trazodone according to its own documents (trazodone SmPC, AEMPS; trazodone label, US Food and Drug Administration, FDA), and clarithromycin according to its own (clarithromycin SmPC, AEMPS, and FDA label). When QT-prolonging drugs are combined, their effects on the heart may add up, and with a strong CYP3A4 inhibitor the risk of trazodone adverse reactions, including cardiac arrhythmias, may increase (trazodone FDA label).
Symptoms
QT prolongation itself causes no symptoms and is seen only on an electrocardiogram (ECG). Ventricular arrhythmias, including torsades de pointes, cause abnormal heartbeats, dizziness and fainting (trazodone label, US Food and Drug Administration, FDA), and fatal cases have been reported with clarithromycin (clarithromycin FDA label). Higher trazodone levels show as nausea, syncope and low blood pressure (trazodone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In older people, trazodone more often causes orthostatic hypotension and somnolence (trazodone SmPC, AEMPS).
Management
Avoid the combination. The trazodone label from the US Food and Drug Administration (FDA) says to avoid trazodone with CYP3A4 inhibitors, naming clarithromycin among them, and with drugs that prolong the QT interval (trazodone FDA label). The Spanish trazodone summary of product characteristics (SmPC) says to avoid co-administration with strong CYP3A4 inhibitors when possible (trazodone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and clarithromycin is a strong inhibitor of this enzyme according to its own SmPC (clarithromycin SmPC, AEMPS). The US clarithromycin label also says to avoid clarithromycin in patients receiving drugs that prolong the QT interval (clarithromycin FDA label). If the combination cannot be avoided, consider a lower trazodone dose (trazodone SmPC, AEMPS; trazodone FDA label). Clarithromycin is contraindicated in patients with a history of QT prolongation, ventricular arrhythmias, low potassium or low magnesium (clarithromycin SmPC, AEMPS), and avoid trazodone in patients with a history of arrhythmias, symptomatic bradycardia, low potassium or magnesium, or congenital QT prolongation (trazodone FDA label). Use trazodone with caution in heart disease, including conduction disorders and QT prolongation (trazodone SmPC, AEMPS), and clarithromycin with caution in coronary artery disease, severe heart failure, conduction disorders and clinically relevant bradycardia (clarithromycin SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Clarithromycin tablets (clarithromycin) prescribing information (2026)– FDA, DailyMed setid 4d42821d-ce7a-7d64-e063-6294a90a0875 (Solaris Pharma Corporation), version 2, revised 04/2026, sections 4, 5.2 and 7
- AEMPS: Ficha técnica: Claritromicina, Klacid 500 mg (nº registro 60515) (2024)– AEMPS, CIMA, nº registro 60515 (Klacid 500 mg comprimidos recubiertos con película), revisión 10/2024, secciones 4.3, 4.4 y 4.5
- FDA: RALDESY (trazodone hydrochloride) prescribing information (2026)– FDA, DailyMed setid 34708cc1-b0b2-4fd0-b9f3-7f008b457fc9 (Validus), revisión 09/2026 (versión 6), secciones 5.2, 5.3, 5.9 y 7
- AEMPS: Ficha técnica: Trazodona, Deprax 100 mg (nº registro 78762), sección 4.5 (2023)– AEMPS, CIMA, nº registro 78762 (Deprax 100 mg comprimidos recubiertos con película, Angelini Pharma España), revisión 11/2023, secciones 4.4, 4.5 y 5.1